Publications by authors named "E Galanis"

In May 2017, whole-genome sequencing (WGS) became the primary subtyping method for in Canada. As a result of the increased discriminatory power provided by WGS, 16 multi-jurisdictional outbreaks of associated with frozen raw breaded chicken products were identified between 2017 and 2019. The majority (15/16) were associated with , while the remaining outbreak was associated with Heidelberg.

View Article and Find Full Text PDF

Importance: Molecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet there remains a great deal of heterogeneity in using such biomarker testing across institutions and hospital systems. This is in large part because there is a persistent reluctance among third-party payers to cover molecular testing.

View Article and Find Full Text PDF

This study investigated cases of pregnancy-related listeriosis in British Columbia (BC), Canada, from 2005 to 2014. We described all diagnosed cases in pregnant women ( = 15) and neonates ( = 7), estimated the excess healthcare costs associated with listeriosis, and calculated the fraction of stillbirths attributable to listeriosis, and mask cell sizes 1-5 due to data requirements. Pregnant women had a median gestational age of 31 weeks at listeriosis onset (range: 20-39) and on average delivered at a median of 37 weeks gestation (range: 20-40).

View Article and Find Full Text PDF
Article Synopsis
  • MEDI5395 is a modified Newcastle disease virus designed to boost immune response against tumors, showing promise when combined with durvalumab, an approved immune checkpoint inhibitor.
  • The study involved advanced solid tumor patients who had previously failed treatments, administering MEDI5395 through six intravenous doses while durvalumab was given every four weeks.
  • Results indicated that all patients experienced adverse events, with fatigue and nausea being the most common, and the maximum tolerated dosage was determined to be 10 focus forming units for both MEDI5395 and durvalumab.
View Article and Find Full Text PDF